What is TOI's current stock price?

As of now, TOI is trading at $3.78, with a daily change of +0.53%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

TOI Stock Analysis & IQ Rating | The Oncology Institute

TOI

The Oncology Institute

$3.78

+$0.02 | +0.53%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$4.88

MKT CAP

$371.88M

52W Low

$0.17

VOL

$2.32M

P/E Ratio

N/A

AVG VOL

$2.71M

RSI

58.46

TREND

Sideways

TOI Stock IQ

Login to see The Oncology Institute (TOI) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

TOI Target Price

Login to display

Strengths

TOI Rewards

Earnings are forecast to grow

TOI Rewards

Investors confidence is positive

Technical Indicators

TOI Technical Indicators

5+ Days Up

TOI Price Performance

$3.78 (0.00%)

$3.12 (+21.15%)

$3.65 (+3.56%)

$0.32 (+1081.25%)

1year

6month

3month

1month

TOI Risk Level

TOI has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Fair

LOW

HIGH

TOI Analysts Opinion

TOI overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

TOI Analysts Opinion

TOI Analysts opinion is negative and it remained unchanged from the past 3 months

TOI Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

72%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

TOI Street Sentiment

TOI Street Sentiment is bullish and have positive views on the near-term outlook

TOI Performance Sentiment

Sentiments overview associated with TOI events and the stock performance.

72%

16%

Positive

Negative

18 out of 25
events present

4 out of 25
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$3.78

Resistance
Price

$2.94

Current Price Range

$4.75

Show methods +

TOI Latest Analysis +

Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight. ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling unprecedented. Major pharmaceutical developers such as Johnson & Johnson Arcellx Gilead Bristol Myers Squibb Regeneron AbbVie CellCentric...

Thu Dec 11, 2025

$3.76 | +7.43%

Activity

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules. ) the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (".Citius Pharma".) (NASDAQ:) today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor priced at-the-market under Nasdaq rules for the purchase and sale of 1284404 shares of its common stock at a purchase price

Wed Dec 10, 2025

$3.50 | +3.55%

Activity

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules. Proceeds strengthen cash position and support commercial launch of LYMPHIR™. a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)) the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (".Citius Pharma".) (NASDAQ:) today announced that it has entered into a definitive agreement with a single healthcare-focused investor for th

Tue Dec 9, 2025

$3.38 | +6.29%

Activity

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim. Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across LYMPHIR international availability extends to 19 markets outside the United States) the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (".Citius Pharma".) (NASDAQ:) today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve T

Thu Dec 4, 2025

$3.23 | +5.21%

Activity

Citius Oncology Launches LYMPHIR The First CTCL Systemic Therapy In Over 7 Years . (RTTNews) - Citius Oncology Inc. (CTOR) the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the United States commercial launch of LYMPHIR a new immunotherapy for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

Tue Dec 2, 2025

$2.96 | +0.68%

Activity

Biotech Valuations Rise as New Clinical Platforms Show Progress. AUSTIN Texas Nov. 24 2025 (GLOBE NEWSWIRE) -- : As advanced biotech programs move closer to commercialization fair-value adjustments under United States Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact giving investors clearer insight into how innovatio

Mon Nov 24, 2025

$3.04 | -2.88%

Activity

Potential

FAQ About TOI Stock Insights

What is TOI current stock price?

What are TOI stock strengths?

What is TOI Risk Level?

What is TOI market cap and volume?

What is TOI current Stock IQ?

Should I buy TOI stock right now?

Is TOI a Strong Buy right now?

What does a 'Strong Buy' rating mean for TOI?

What does a 'Strong Sell' rating mean for TOI?

What factors influence TOI's Stock IQ?

Explore our TOI Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored TOI Stock Strategies
Effective Risk Management

FIND US ON

Receive our TOI Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

TOI

The Oncology Institute

Current Price

$3.78

+$0.02 | +0.53%

52W High

$4.88

MKT CAP

$371.88M

52W Low

$0.17

VOL

$2.32M

P/E Ratio

N/A

AVG VOL

$2.71M

RSI

58.46

TREND

Sideways

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

TOI Rewards

Earnings are forecast to grow

TOI Rewards

Investors confidence is positive

Technical Indicators

TOI Technical Indicators

5+ Days Up

TOI Price Performance

$3.78 (0.00%)

$3.12 (+21.15%)

$3.65 (+3.56%)

$0.32 (+1081.25%)

1year

6month

3month

1month

TOI Analysts Opinion

TOI Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

TOI Analysts Opinion

TOI Analysts opinion is negative and it remained unchanged from the past 3 months

TOI Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

72%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

TOI Street Sentiment

TOI Street Sentiment is bullish and have positive views on the near-term outlook

TOI Risk Level

TOI has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Fair

LOW

HIGH

TOI Performance Sentiment

Sentiments overview associated with TOI events and the stock performance.

72%

16%

Positive

Negative

18 out of 25
events present

4 out of 25
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$3.78

Resistance
Price

$2.94

Current Price Range

$4.75

Show methods +

TOI Stock IQ

Login to unlock The Oncology Institute (TOI) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

TOI Latest Analysis

Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight. ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling unprecedented. Major pharmaceutical developers such as Johnson & Johnson Arcellx Gilead Bristol Myers Squibb Regeneron AbbVie CellCentric...

Thu Dec 11, 2025

$3.76 | +7.43%

Activity

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules. ) the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (".Citius Pharma".) (NASDAQ:) today announced the closing of its previously announced registered direct offering with a single healthcare-focused investor priced at-the-market under Nasdaq rules for the purchase and sale of 1284404 shares of its common stock at a purchase price

Wed Dec 10, 2025

$3.50 | +3.55%

Activity

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules. Proceeds strengthen cash position and support commercial launch of LYMPHIR™. a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)) the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (".Citius Pharma".) (NASDAQ:) today announced that it has entered into a definitive agreement with a single healthcare-focused investor for th

Tue Dec 9, 2025

$3.38 | +6.29%

Activity

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim. Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across LYMPHIR international availability extends to 19 markets outside the United States) the oncology-focused subsidiary of Citius Pharmaceuticals Inc. (".Citius Pharma".) (NASDAQ:) today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve T

Thu Dec 4, 2025

$3.23 | +5.21%

Activity

Citius Oncology Launches LYMPHIR The First CTCL Systemic Therapy In Over 7 Years . (RTTNews) - Citius Oncology Inc. (CTOR) the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the United States commercial launch of LYMPHIR a new immunotherapy for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

Tue Dec 2, 2025

$2.96 | +0.68%

Activity

Biotech Valuations Rise as New Clinical Platforms Show Progress. AUSTIN Texas Nov. 24 2025 (GLOBE NEWSWIRE) -- : As advanced biotech programs move closer to commercialization fair-value adjustments under United States Generally Accepted Accounting Principles (GAAP) are increasingly recognized as meaningful signals of real scientific and business advancement. These valuations help translate research achievements into quantifiable economic impact giving investors clearer insight into how innovatio

Mon Nov 24, 2025

$3.04 | -2.88%

Activity

Potential

Discover TOI Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of TOI. We're here to help you make informed investment decisions today.

FIND US ON

Receive our TOI Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

TOI Stock trends

TOI Stock performance

TOI Stock analysis

TOI investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing TOI

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing TOI

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

TOI Stock Analysis & IQ Rating | The Oncology Institute

TOI Stock IQ

TOI Target Price

TOI Risk Level

TOI Analysts Opinion

TOI Street Sentiment

TOI Performance Sentiment

Technical Price Levels

Explore our TOI Stock insights

Receive our TOI Daily Alerts

TOI Street Sentiment

TOI Risk Level

Technical Price Levels

Discover TOI Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of TOI. We're here to help you make informed investment decisions today.

Receive our TOI Daily Alerts

TOI Runner Alarm